| 2026-08-07 | Press release | Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update |
| 2026-07-28 | Press release | Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Acti |
| 2026-07-21 | Press release | Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Sp |
| 2026-06-12 | Press release | Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds |
| 2026-06-11 | Press release | Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds |
| 2026-05-27 | Press release | Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing |
| 2026-05-20 | Press release | Atossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Du |
| 2026-05-14 | Press release | Atossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER |
| 2026-05-06 | Press release | Atossa Therapeutics Announces Publication of KARISMA Endoxifen Trial Demonstrating Significant Reduction in Mammographic |
| 2026-05-04 | Press release | Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for McCune-Albright Syndrome |
| 2026-03-19 | Press release | Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives |
| 2026-03-12 | Press release | Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scient |
| 2026-02-11 | Press release | Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook |
| 2026-02-11 | Presentation | View Corporate Presentation |
| 2026-02-05 | Press release | Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reaut |
| 2026-01-21 | Press release | Atossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025 |
| 2026-01-16 | Press release | Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystro |
| 2026-01-06 | Press release | Atossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for M |
| 2025-12-17 | Press release | Atossa Therapeutics Wins 2025 Clinical Trials Arena Research and Development Excellence Award in Precision Endocrine The |
| 2025-12-15 | Press release | Atossa Therapeutics Presents Four Clinical Trial Updates Highlighting (Z)-Endoxifen Research at the 2025 San Antonio Bre |
| 2025-12-11 | Press release | Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy |
| 2025-12-09 | Press release | Atossa Therapeutics Announces Issuance of U.S. Patent Covering Enteric Oral (Z)-Endoxifen Formulations and Methods of Tr |
| 2025-12-04 | Press release | Atossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across Breast Cancer Continuum |
| 2025-12-02 | Press release | Insilico Medicine and Atossa Therapeutics Publish AI-Driven Study in Nature Scientific Reports Identifying (Z)-Endoxifen |
| 2025-11-17 | Press release | Atossa Highlights Emerging Opportunity for (Z)-Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Ca |
| 2025-11-06 | Press release | Atossa Therapeutics Announces Acceptance of Four Abstracts Highlighting (Z)-Endoxifen Research for Presentation at the 2 |
| 2025-10-21 | Press release | Atossa Therapeutics Highlights Progress in RECAST™ DCIS Platform Trial at Early Detection Research Conference; Laura Ess |
| 2025-10-15 | Press release | Atossa Therapeutics to Present at the Maxim Growth Summit 2025 |
| 2025-10-14 | Press release | Atossa Appoints Mark Daniel, CPA, as Chief Financial Officer to Lead Finance, Systems, and Capital Strategy for Commerci |
| 2025-03-25 | Press release | News Release |
| 2024-11-12 | Press release | News Release |
| 2024-08-12 | Press release | News Release |
| Earnings deck | Fourth Quarter and Full Year 2024 Financial Results |